Results 21 to 30 of about 3,351 (178)

Studies of quantum mechanics/molecular docking on zanubrutinib as potential repurposed against Covid-19 [PDF]

, 2022
. Recently, Zanubrutinib, as a novel, selective covalent and potent inhibitor Bruton’s tyrosine kinase (BTK), has been used to treat COVID-19 patients. In this regard, the interaction of Zanubrutinib with Bruton’s tyrosine kinase (BTK) inhibitor studied.
Madadi Mahani , Nosrat, Zia Mohammadi , Sayed   +1 more
core   +2 more sources

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160-mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers. [PDF]

Clin Pharmacol Drug Dev
Abstract Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed.
Tariq B, Lin C, Mundra V, Gao Y, Zhang D, Ou YC.   +5 more
europepmc   +2 more sources

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

CPT: Pharmacometrics & Systems Pharmacology, 2021
A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on the exposures ...
Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou   +6 more
doaj   +1 more source

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study [PDF]

, 2023
The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed ...
Ardeshna K., Bijou F., Browett P., Co M., Coleman M., Delarue R., Hawkes E. A., Ho S. -J., Hu B., Jin J., Ke X., Leitch S., Liang Z., Linton K. M., McKay P., Opat S., Sobieraj-Teague M., Sun M., Tankersley C., Tedeschi A., Thieblemont C., Trotman J., Walker P., Xu J., Zhou K., Zinzani P. L.   +25 more
core   +1 more source

Zanubrutinib-induced liver injury: a case report and literature review

BMC Gastroenterology, 2021
Background Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies.
Edmond Atallah, Pramudi Wijayasiri, Nicole Cianci, Khorrum Abdullah, Abhik Mukherjee, Guruprasad P. Aithal   +5 more
doaj   +1 more source

Bilateral Cystoid Macular Edema with Zanubrutinib Therapy: A Case Report

Case Reports in Oncology, 2023
We present a patient with recurrent mantle cell lymphoma (MCL) who was treated with zanubrutinib, a Bruton’s tyrosine kinase inhibitor. He subsequently developed bilateral cystoid macular edema (CME) in both eyes.
Dante Pennipede, Harrison Sciulli, Radwan Ajlan   +2 more
doaj   +1 more source

Current Treatment Options in CLL [PDF]

, 2021
After impressive developments in recent years with the rise of new targeted agents, chemoimmunotherapy (CIT) only plays a minor role in the treatment of patients with chronic lymphocytic leukemia (CLL).
Bewarder, Moritz, Kaddu-Mulindwa, Dominic, Stilgenbauer, Stephan, Thurner, Lorenz   +3 more
core   +1 more source

Triplet regimens for frontline treatment of CLL-Great company or just a crowd? [PDF]

Hemasphere
Abstract Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high‐risk biological subgroups, and indefinite covalent Bruton ...
McKeague S, Seymour JF.
europepmc   +2 more sources

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy. [PDF]

Eur J Haematol
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Oliva S, Molica S.
europepmc   +2 more sources

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma [PDF]

, 2021
Purpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling.
Ardeshna K., Bijou F., Browett P., Cappellini M., Chan H., Co M., Coleman M., Hawkes E. A., Ho S. -J., Hu B., Huang J., Jin J., Ke X., Li X., Linton K., Mapp S., Marcus R., McKay P., Opat S., Portell C. A., Sobieraj-Teague M., Sun M., Talaulikar D., Tankersley C., Tedeschi A., Thieblemont C., Trotman J., Walker P., Zhou K. -S., Zhou W., Zinzani P. L.   +30 more
core   +1 more source